Preclinical Analysis of JAA-F11, a Specific Anti-Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging.
In conclusion, the tumor reactivity of JAA-F11 supports the continued development of JAA-F11 as a targeted cancer therapeutic for multiple cancers, including those with unmet need.
PMID: 29477636 [PubMed - as supplied by publisher]
Source: Translational Oncology - Category: Cancer & Oncology Authors: Karacosta LG, Fisk JC, Jessee J, Tati S, Turner B, Ghazal D, Ludwig R, Johnson H, Adams J, Sajjad M, Koury S, Roy R, Olson JR, Rittenhouse-Olson K Tags: Transl Oncol Source Type: research
More News: Bladder Cancer | Breast Cancer | Cancer | Cancer & Oncology | Chemistry | Clinical Trials | Colon Cancer | Colorectal Cancer | HER2 | Hormones | Lung Cancer | Ovarian Cancer | Ovaries | PET Scan | Study